Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents
January 03, 2024 07:00 ET
|
Invivyd
EUA submission is based on positive initial results from the ongoing CANOPY Phase 3 pivotal clinical trial and ongoing in vitro neutralization activity against relevant SARS-CoV-2 variantsVYD222...
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
December 18, 2023 07:00 ET
|
Invivyd
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 09, 2023 16:01 ET
|
Invivyd
Enrollment completed in CANOPY Phase 3 pivotal clinical trial investigating VYD222 for the prevention of symptomatic COVID-19Company expects to have initial CANOPY primary endpoint data by late 2023...
Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights
November 02, 2023 16:01 ET
|
Invivyd
WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
Invivyd to Participate in Upcoming Investor Conferences
October 31, 2023 16:01 ET
|
Invivyd
WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19
September 11, 2023 07:00 ET
|
Invivyd
WALTHAM, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
Invivyd to Participate in Upcoming Investor Conferences
September 06, 2023 07:00 ET
|
Invivyd
WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
Invivyd Appoints William Duke as Chief Financial Officer
September 05, 2023 07:00 ET
|
Invivyd
WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights
August 10, 2023 16:01 ET
|
Invivyd
Reported positive initial Phase 1 VYD222 clinical trial data, including favorable safety data and robust serum neutralizing titers from all three dose levels testedPlans to pursue rapid initiation of...
Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights
August 03, 2023 16:01 ET
|
Invivyd
WALTHAM, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...